GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » eFFECTOR Therapeutics Inc (NAS:EFTR) » Definitions » Equity-to-Asset

eFFECTOR Therapeutics (eFFECTOR Therapeutics) Equity-to-Asset : -0.28 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is eFFECTOR Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. eFFECTOR Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-5.80 Mil. eFFECTOR Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $20.54 Mil.

The historical rank and industry rank for eFFECTOR Therapeutics's Equity-to-Asset or its related term are showing as below:

EFTR' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.92   Med: -0.07   Max: 0.32
Current: -0.28

During the past 4 years, the highest Equity to Asset Ratio of eFFECTOR Therapeutics was 0.32. The lowest was -7.92. And the median was -0.07.

EFTR's Equity-to-Asset is ranked worse than
87.42% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs EFTR: -0.28

eFFECTOR Therapeutics Equity-to-Asset Historical Data

The historical data trend for eFFECTOR Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

eFFECTOR Therapeutics Equity-to-Asset Chart

eFFECTOR Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
-7.92 0.32 0.13 -0.28

eFFECTOR Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 -0.22 0.10 -0.20 -0.28

Competitive Comparison of eFFECTOR Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, eFFECTOR Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


eFFECTOR Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, eFFECTOR Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where eFFECTOR Therapeutics's Equity-to-Asset falls into.



eFFECTOR Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

eFFECTOR Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-5.795/20.544
=

eFFECTOR Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-5.795/20.544
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


eFFECTOR Therapeutics  (NAS:EFTR) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


eFFECTOR Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of eFFECTOR Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


eFFECTOR Therapeutics (eFFECTOR Therapeutics) Business Description

Traded in Other Exchanges
Address
142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).
Executives
Sr One Capital Fund I Aggregator Lp 10 percent owner C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Christopher B Ehrlich director, 10 percent owner, officer: Chief Executive Officer 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Mayank Gandhi officer: Chief Business Officer 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Douglas J Warner officer: Chief Medical Officer C/O EFFECTOR THERAPEUTICS, INC., 142 NORTH CEDROS AVENUE, SUITE B, SOLANA BEACH CA 92075
Presidio Management Group X Llc 10 percent owner 2735 SAND HILL ROAD, MENLO PARK CA 94025
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Genesis Uk Llc 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004
Carlyle Investment Management Llc 10 percent owner 1001 PENNSYLVANIA AVE. N.W., WASHINGTON DC 20004
Carlyle Holdings I L.p. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Inc. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Tc Group, Llc 10 percent owner C/O CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE NW SUITE 220 S, WASHINGTON DC 20004
Cg Subsidiary Holdings L.l.c. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Holdings I Gp Sub L.l.c. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Gallagher Brian M. Jr. director, 10 percent owner C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Stephen T Worland director, officer: President and Chief Executive 9050 CAMINO SANTA FE, SAN DIEGO CA 92121

eFFECTOR Therapeutics (eFFECTOR Therapeutics) Headlines

From GuruFocus

eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference

By Stock market mentor Stock market mentor 01-30-2023